Early Academic Pursuits 📚
Dr. Matheus Sewastjanow-Silva’s academic journey began at the Federal University of Minas Gerais (UFMG), Brazil, where he completed his Doctor of Medicine (M.D.) degree from 2012 to 2018. During his time at UFMG, he participated in various internships, enhancing his medical expertise across multiple fields, including rural and family medicine, as well as specialized training in dermatology, plastic surgery, and transplant surgery. Additionally, Dr. Sewastjanow-Silva received specialized training at prestigious institutions like A.C. Camargo Cancer Center and Jackson Memorial Hospital, further refining his skills in oncology and surgical specialties.
Professional Endeavors 💼
Dr. Sewastjanow-Silva’s professional career spans various roles at renowned institutions. Currently, he serves as a Research Investigator at the University of Texas MD Anderson Cancer Center (07/2024-present), where he contributes significantly to Shirley Su’s research group in the Department of Head and Neck Surgery. His responsibilities include managing clinical studies/trials databases, manuscript writing, and data analysis, using advanced tools like RedCap, Epic/SlicerDicer, and Prometheus. His prior experience at MD Anderson under Jaffer Ajani’s lab focused on clinical studies and research related to gastrointestinal oncology, where he gained expertise in DNA/RNA extraction, cell culture, and Western Blotting. Additionally, he worked as a physician in several clinics in Brazil, handling outpatient family medicine and emergency care, including COVID-19 patients, displaying his broad clinical knowledge and commitment to patient care.
Contributions and Research Focus 🧬
Dr. Sewastjanow-Silva’s primary research interests lie in oncology, particularly in gastrointestinal cancer and head and neck surgery. Throughout his career, he has been involved in multiple research projects aimed at improving clinical outcomes through the analysis of clinical samples, patient enrollment, and database management. His work involves cutting-edge technologies for analyzing cancer treatment responses, molecular genetics, and experimental models. He has authored and contributed to numerous publications and poster presentations in notable conferences such as the AACR Meeting and ASCO GI, focusing on cancer research and surgical techniques.
Impact and Influence 🌍
Dr. Sewastjanow-Silva has had a significant impact on the field of oncology, particularly through his contributions to clinical research. As a research investigator, he is at the forefront of studying innovative cancer therapies and advancing clinical knowledge in head and neck surgery. He is a respected member of the scientific community, holding memberships in the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Furthermore, his leadership role in organizing multiple cancer and surgical conferences demonstrates his influence in the academic community, aiming to foster collaboration and drive advancements in cancer research.
Academic Cites 📑
Dr. Sewastjanow-Silva’s academic contributions have garnered recognition within the scientific community, exemplified by his presentations at prominent conferences and his active participation in research publications. His involvement in studies and research protocols has significantly contributed to understanding cancer treatment and surgical outcomes. As a member of the Sigma Xi Scientific Research Honor Society (2024), Dr. Sewastjanow-Silva’s academic citations reflect his growing influence in the field, with numerous abstract and manuscript submissions to journals and conferences.
Technical Skills ⚙️
Dr. Sewastjanow-Silva possesses a robust skill set in both clinical and laboratory settings. His technical expertise includes advanced knowledge in the use of clinical trial management systems like RedCap, Epic/SlicerDicer, and Prometheus. He is proficient in molecular biology techniques such as DNA/RNA extraction, qPCR, Western Blotting, and viral transfections. In addition, he is skilled in cell culture, tissue staining, flow cytometry, and immunohistochemistry. These technical skills allow him to engage in high-level research and clinical analysis, contributing to the progression of cancer therapy.
Teaching Experience 🎓
As a Teaching Assistant at UFMG, Dr. Sewastjanow-Silva mentored first-year medical students, contributing to the academic development of future healthcare professionals. His involvement in various student interest groups, such as those focused on dermatology, anesthesiology, and plastic surgery, highlights his leadership and teaching skills. His role as a coordinator for the Plastic Surgery Student Interest Group further underscores his commitment to fostering the next generation of medical experts.
Leadership and Future Contributions 🌟
Dr. Sewastjanow-Silva’s leadership experience is extensive, having coordinated multiple medical and scientific initiatives at UFMG, such as organizing national campaigns for cancer and burn awareness, as well as medical education activities. As he continues his career at MD Anderson, Dr. Sewastjanow-Silva’s contributions to cancer research and clinical oncology are expected to further elevate his influence. His future endeavors will likely include continuing groundbreaking research, developing novel therapeutic strategies, and further mentoring and educating students and young researchers. His deep commitment to the advancement of medical science and patient care will undoubtedly shape the future of oncology.
Legacy and Lasting Impact 🏆
Dr. Sewastjanow-Silva’s legacy will be defined by his consistent commitment to advancing the field of oncology and his contributions to cancer research and clinical care. Through his extensive work in both Brazil and the United States, he has bridged international research gaps and improved clinical practices. His awards, including the “Young Talent for Science” and honors from Sigma Xi, reflect the significant strides he has made. Looking ahead, Dr. Sewastjanow-Silva will continue to impact the global medical community through innovation, research, and education, shaping the future of cancer care worldwide.